Apollo Hospitals Enterprise Limited has informed the Exchange about General Updates
APOLLOHOSP · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 3.1 pts more than Nifty 100 and 3.2 pts more than its Hospital peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Apollo Hospitals reported strong FY2026 results with consolidated revenue growing 15.7% to Rs 252,285 million and PAT surging 33.1% to Rs 20,027 million. Standalone revenue rose 13.7% to Rs 93,262 million with PAT up 15.1% to Rs 14,926 million. The Board recommended a final dividend of Rs 10 per share (200%), following an interim dividend of same amount already paid. Key leadership re-appointments include Dr Prathap C Reddy as Executive Chairman for 2 years and Ms Rama Bijapurkar as Independent Director for 5 years. Two significant corporate actions were approved: merger of Apollo Hospitals North Limited (wholly owned subsidiary) into the Company, and a transaction where Apollo Health and Lifestyle Limited will divest stakes in two subsidiaries to Kids Clinic India Limited (Cloudnine) for Rs 15,500 million enterprise value. Auditors Deloitte Haskins & Sells LLP issued unmodified opinions on both standalone and consolidated results.
Strong 33% PAT growth on consolidated basis and 15.7% revenue growth indicate robust operational performance. Strategic transactions and merger announcements signal ongoing portfolio restructuring which could create shareholder value. The positive dividend outlook and clean audit opinion are supportive for the stock.